Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypothalamic Obesity
Conditions
Hypothalamic Obesity, Prader-Willi Syndrome, PWS
Trial Timeline
Mar 5, 2024 → Nov 1, 2028
NCT ID
NCT06239116About Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718
Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) + Part C: RM-718 + Part D: RM-718 is a phase 1/2 stage product being developed by Rhythm Pharmaceuticals for Hypothalamic Obesity. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06239116. Target conditions include Hypothalamic Obesity, Prader-Willi Syndrome, PWS.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06239116 | Phase 1/2 | Recruiting |
Competing Products
7 competing products in Hypothalamic Obesity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Octreotide | Novartis | Approved | 85 |
| Mibavademab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide + Placebo | Rhythm Pharmaceuticals | Phase 3 | 74 |
| Setmelanotide | Rhythm Pharmaceuticals | Phase 2 | 49 |
| Bivamelagon | Rhythm Pharmaceuticals | Phase 2 | 49 |
| LB54640 + Placebo | Rhythm Pharmaceuticals | Phase 2 | 49 |